Evidence map›Paper›PMID 38509261›Full record

ReviewEndocrine2024

Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons.

Roberta Modica, Anna La Salvia, Alessia Liccardi, Alessia Cozzolino, Antonella Di Sarno, Flaminia Russo, Annamaria Colao, Antongiulio Faggiano, NIKE group

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Metabolic changes in neuroendocrine neoplasms.Cellular and molecular life sciences : CMLS · 2025
    Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Roberta ModicaEndocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, 80131, Naples, Italy. roberta.modica@unina.it.ORCID 0000-0002-3768-5803
Anna La SalviaNational Center for Drug Research and Evaluation, National Institute of Health (ISS), 00161, Rome, Italy.ORCID 0000-0002-5020-8657
Alessia LiccardiEndocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, 80131, Naples, Italy.ORCID 0000-0003-1784-5491
Alessia CozzolinoDepartment of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.ORCID 0000-0001-8614-5873
Antonella Di SarnoEndocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, 80131, Naples, Italy.
Flaminia RussoEndocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome, 00189, Rome, Italy.ORCID 0000-0003-4703-4358
Annamaria ColaoEndocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, 80131, Naples, Italy.ORCID 0000-0001-6986-266X
Antongiulio FaggianoEndocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome, 00189, Rome, Italy.ORCID 0000-0002-9324-3946
NIKE group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNeuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies originating from cells with a neuroendocrine phenotype. The complex relationship between lipid metabolism and cancer is gaining interest and a potential anti-cancer effect of lipid lowering agents is being considered. This review aims to discuss the current understanding and treatment of dyslipidaemia in NENs, focusing on the role of lipid lowering agents, including new therapeutic approaches, and future perspectives as possible tool in cancer prevention and tumor-growth control.

methodsWe performed an electronic-based search using PubMed updated until December 2023, summarizing the available evidence both in basic and clinical research about lipid lowering agents in NENs.

resultsDyslipidemia is an important aspect to be considered in NENs management, although randomized studies specifically addressing this topic are lacking, unlike other cancer types. Available data mainly regard statins, and in vitro studies have demonstrated direct antitumor effects, including antiproliferative effects in some cancers, supporting possible pleiotropic effects also in NENs, but data remain conflicting. Ezetimibe, omega 3-fatty acids, fibrates and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) may enhance the regulation of lipid homeostasis, as demonstrated in other cancers.

conclusionsTargeting dyslipidemia in NENs should be part of the multidisciplinary management and an integrated approach may be the best option for both metabolic and tumor control. Whether lipid lowering agents may directly contribute to tumor control remains to be confirmed with specific studies, focusing on association with other metabolic risk, disease stage and primary site.

Indexed as

DyslipidemiasHypolipidemic AgentsNeuroendocrine TumorsHumansLipid MetabolismHypolipidemic Agentscancer therapyDyslipidemialipid-lowering agentslipid metabolismneuroendocrine neoplasmneuroendocrine tumor

Identifiers

PMID38509261
PMCPMC11291585

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.